OrientSciences NewsPeptide and medical research from around the world, reported in English
5 min read
ObesityPaediatric researchGLP-1

Semaglutide in children under 12: what the full STEP Young paper shows, and what it leaves open

Full STEP Young data in the NEJM: BMI fell 13.5% in children aged 6 to under 12 on semaglutide. What the paper shows, and what its public abstract leaves open.

The first large trial of a GLP-1 drug in children under 12 was published yesterday in The New England Journal of Medicine and presented at ObesityWeek in Washington. In STEP Young, children aged 6 to under 12 with obesity who took weekly semaglutide, the active ingredient in Wegovy, saw their body mass index fall by 13.5 percent at 68 weeks, while it rose 2.7 percent on placebo.

The timing matters. Wegovy is currently approved from the age of 12, and prescriptions of GLP-1 drugs to US children under 12 have risen more than 300 fold since 2019, according to a study published in early September, well ahead of any approval. This is the first rigorous evidence for that age group. We worked from the paper's abstract and PubMed record, Novo Nordisk's release and trade coverage. The full text, appendix and protocol sit behind a sign in.

The trial

STEP Young randomised 167 children in a two to one ratio, 112 to semaglutide and 55 to placebo. Both groups received lifestyle counselling, with a reduced calorie diet and more physical activity. The maximum dose was 1.7 mg or 2.4 mg depending on baseline body weight, and treatment ran for 104 weeks, followed by a seven week washout. More than 85 percent of the children had class 2 or class 3 obesity. The trial ran from July 2023 to July 2026, is sponsored by Novo Nordisk and is registered as NCT05726227. The first author is Ania Jastreboff of Yale.

The main result

At week 68, the primary endpoint, BMI fell an estimated 13.5 percent with semaglutide and rose 2.7 percent with placebo, a difference of 16.2 percentage points (95 percent confidence interval 12.9 to 19.4, P below 0.001). If every child had stayed on treatment, Novo reports, the figures would be a fall of 17.4 percent and a rise of 2.2 percent.

The category results are what clinicians will notice. At week 68, 79 percent of children on semaglutide moved down a BMI category, against 23 percent on placebo, and 38 percent against 2 percent ended below the 95th percentile for age and sex, the usual threshold for obesity in children. Novo's September topline put the second figure at 40.4 percent, a number that assumes full adherence, so the two are not directly comparable.

Week 104

At week 104 the abstract reports BMI down 9.4 percent with semaglutide and up 8.4 percent with placebo, a difference of 17.8 percentage points (95 percent confidence interval 13.3 to 22.2). Read next to the week 68 figures, the semaglutide group's fall is smaller than it was at 68 weeks, and the wider gap comes mostly from BMI continuing to rise on placebo. The figures come from the abstract and may rest on different analysis sets.

Safety

Adverse events occurred in 96 percent of children on semaglutide and 93 percent on placebo. Gastrointestinal events were the most common and were more frequent with semaglutide. The abstract says they led one child to stop treatment. Healio's coverage gives 4 percent on semaglutide and 2 percent on placebo stopping for adverse events of any kind, and describes no new safety concerns.

Beyond BMI

Healio also reports cardiometabolic benefits. In an exploratory analysis of children with prediabetes at baseline, 93 percent on semaglutide had an HbA1c below 5.7 percent at week 68, against 56 percent on placebo. A paediatrician quoted by MDLinx welcomed the result but noted that the 40.4 percent figure assumes children took the drug as prescribed, that 68 weeks is short for children who may need treatment for years, and that BMI is one measure among several.

What changes now

The evidence arrives while use is already running ahead of the label. Whether regulators extend Wegovy's approval below the age of 12 is not yet known, and the material we reviewed does not say when Novo plans to file.

What is still unknown

Most of what a clinician would want next sits behind the journal's sign in. The abstract gives no rates for individual adverse events, serious adverse events, or gallbladder, pancreatitis and psychiatric events. It does not report growth in height or pubertal development, which matter most in children, nor week 104 body weight or most cardiometabolic markers, and it does not describe what happened during the seven week washout. The authors' own list of limitations and the funder's role statement were not available to us.

Longer follow up is the largest gap. The trial covers two years in children who may need treatment for far longer, and whether the benefit holds, and what happens after treatment stops, will shape how this evidence is read. OrientSciences worked from the abstract, the PubMed record, Novo Nordisk's release and trade coverage, and did not see the full paper, appendix or protocol.

SOURCES AND FURTHER READING

Share this update

Share this update: https://orientsciences.com/news/semaglutide-children-step-young-nejm-what-it-shows-and-what-is-open

View all weekly news